Folate Receptor-Targeted Liposomes Loaded with Actinomycin X2 Enhance Antitumor Potency for HCCLM3 Hepatocellular Carcinoma Both In Vitro and In Vivo
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Yang Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Laboratory of Antiallerg…. Hauptthemen laut MEDLINE: Liposomes, Carcinoma, Hepatocellular, Dactinomycin, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Zhejiang Sci-Tech University, National Natural Science Foundation of China, Joint foundation of National Administration of Traditional Chinese Medicine and Zhejiang Province.
Abstract (Originalsprache)
Actinomycin X2 (Act.X2), an analog of actinomycin D produced by marine-derived actinomycete Streptomyces sp., has shown promising antitumor activity. This study attempted to improve the delivery efficiency of Act.X2 through a targeted approach. We developed a folate (FA)-modified, Act.X2-loaded liposomal system (FA-Act.X2-Lips) to enhance its targeting specificity and antitumor efficacy against hepatocellular carcinoma (HCC). FA-Act.X2-Lips exhibited a uniform spherical morphology, an average particle size of approximately 139.85 nm, and an encapsulation efficiency of around 88.34%. Cytotoxicity assays demonstrated that FA-Act.X2-Lips have significantly higher cytotoxicity against HCCLM3 cells compared with the unmodified Act.X2-Lips. Additionally, an orthotopic HCC model in mice was established, and tail vein injections of FA-Act.X2-Lips were administered to study targeted drug delivery. Both in vitro targeting studies and in vivo fluorescent imaging assays demonstrated that FA-modified liposomes enhanced tumor-targeting efficiency. In terms of antitumor activity, FA-Act.X2-Lips significantly inhibited tumor growth in HCCLM3 tumor-bearing mice, compared with the free Act.X2 and unmodified Act.X2-Lips, while effectively inducing tumor cell apoptosis without notable toxicity to healthy tissues. The low toxicity profile of FA-Act.X2-Lips addresses a critical clinical limitation of conventional actinomycin-based therapies. These results suggest that FA-Act.X2-Lips hold a therapeutic potential for HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Laboratory of Antiallergy Functional Molecules, College of Life Sciences and Medicine, Zhejian…
- School of Pharmacy and Department of Hepatology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou 311121, China.
- Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310018, China.
- Xinyuan Institute of Medicine and Biotechnology, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, Zhejiang 310018, China.
ORCID-Profile: Bingnan Han
Förderung
- Zhejiang Sci-Tech University
- National Natural Science Foundation of China
- Joint foundation of National Administration of Traditional Chinese Medicine and Zhejiang Province
- Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd Anti-Allergy Functional Molecular Laboratory Cooperation Agreement
Zitieren
APA
Wu, Y., Wang, M., Wang, Y., Bu, F., Yang, Y., Dong, H., Zhang, Z., Zhang, S., Wu, Z., Zhang, X., Chen, J., & Han, B. (2025). Folate Receptor-Targeted Liposomes Loaded with Actinomycin X2 Enhance Antitumor Potency for HCCLM3 Hepatocellular Carcinoma Both In Vitro and In Vivo. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00186
Vancouver
Wu Y, Wang M, Wang Y, Bu F, Yang Y, Dong H, et al. Folate Receptor-Targeted Liposomes Loaded with Actinomycin X2 Enhance Antitumor Potency for HCCLM3 Hepatocellular Carcinoma Both In Vitro and In Vivo. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00186
BibTeX
@article{Wu2025,
author = {Wu, Yang and Wang, Menglan and Wang, Yifan and Bu, Fangtian and Yang, Yuchun and Dong, Heng and Zhang, Zhengguo and Zhang, Shanshan and Wu, Zhenglong and Zhang, Xiaoting and Chen, Jianxiang and Han, Bingnan},
title = {Folate Receptor-Targeted Liposomes Loaded with Actinomycin X2 Enhance Antitumor Potency for HCCLM3 Hepatocellular Carcinoma Both In Vitro and In Vivo},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00186}
}
EUVIMED